We provide biopharmaceutical companies with end-to-end diagnostic solutions inclusive of diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.
To address the increasing complexity of disease biology and new drug mechanisms of action, we employ a technology agnostic approach to uncover insights about the tumor biology and patient’s immune response to cancer for biopharmaceutical therapeutics in clinical development.
We strive to hold ourselves to the highest quality standard so we can provide our biopharmaceutical customers with superior diagnostic solutions to overcome the challenges and risks associated with drug discovery, development, and commercialization through strategic companion diagnostic (CDx) partnering.
We believe partnering with us will help you:
We believe we are the first company with four clinically available, reimbursed, diagnostic tests that address clinical questions across the lung cancer continuum of care. We have nationally-based clinical sales and medical affairs teams who are focused on working with physicians who diagnose and treat lung cancer.
Our unique approach to precision medicine provides timely and actionable clinical information, which we believe improves overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. We are experts in diagnostic reimbursement and have coverage in the US for our lung focused diagnostics.
We have two, highly certified clinical diagnostic testing laboratories. Our Boulder, Colorado-based laboratory is CAP/CLIA/NYS CLEP/ISO 13485-approved and our De Soto, Kansas-based laboratory is CAP/COLA/NYS CLEP-approved.